Drug intelligence / Profile preview

barecetamab

Development stage: Phase 1
Lead developer: ISU Abxis
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

Barecetamab is a drug candidate with a nonproprietary name ending in "-mab," indicating it is a monoclonal antibody. However, there is no publicly available information from major drug databases, regulatory agencies, or scientific literature as of April 2025 regarding its mechanism of action, developer, primary indication, or clinical development status. The absence of data suggests that either the drug is very early in development and not yet disclosed in public sources or the name may be incorrect or not widely recognized.

Other names: barecetamab

Targets

ERBB3 (Erb-b2 receptor tyrosine kinase 3)

Beyond the preview

Go deeper on barecetamab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on barecetamab.

Explore the full profile